Velasco-Velazquez et al. showed that CCL5–CCR5 axis was preferentially activated in more malignant subtype of breast cancer, and that a CCR5 inhibitor, maraviroc, reduced the progression of CCR5+ breast cancer cells in vitro and in vivo35. This evidence concerns the gene CCR5 and breast cancer.